The V.A.C VERAFLOTM therapy system is a technology designed to promote healing in chronic or acutely infected wounds. Currently, acutely infected or chronic non-healing wounds are treated with antibiotics followed by routine assessment, regular cleansing and de-sloughing of the wound, and the application of an appropriate dressing. Wounds may also require debridement to remove necrotic tissue and prepare the wound bed to promote healing. The V.A.C VERAFLOTM therapy system is an alternative to the current standard of care pathway. The technology delivers automated negative pressure wound therapy combined with instillation and dwell time of a topical solution. The company claims this technology is innovative because it allows for repeated cleansing without the need for dressing removal and is the first device to allow the combined instillation of fluid and removal of exudate whilst delivering negative pressure wound therapy. The system is rented from the company and results in a cost of £82.06 per wound per day. The company claims the device will be cost saving to the NHS due to downstream reductions in dressing changes and nursing time.
Status In progress
Process MT
ID number 471

Provisional Schedule

Committee meeting: 1 04 September 2020
Draft guidance 25 September 2020 - 23 October 2020
Committee meeting: 2 13 November 2020
Resolution 14 December 2020

Project Team

Project lead Rebecca Brookfield

Email enquiries


External assessment group NUTH
Manufacturers KCI a subsidiary of Acelity L.P. Inc
Professional groups Association of Breast Surgery
  Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital


Key events during the development of the guidance:

Date Update
02 July 2020 In progress. .
13 May 2020 Schedule affected by COVID-19. NICE is currently working to respond to the operational challenges posed to our normal work programmes. The stakeholders and advisory committees involved in the development of our guidance include a large number of frontline NHS staff. We know that their priority in this crisis is caring for patients and we do not want to draw them away from this vital work. For this reason, we are reviewing all of our guidance in development and will be prioritising only therapeutically critical topics at this time. Therefore, the public consultation for this topic has been paused and will be restarted once it is appropriate to do so; we will advise all registered stakeholders of the new dates in due course. Please accept our apologies for any disappointment this may cause. This is a rapidly changing situation and we will keep our approach under review. Our priority is to support the NHS to care for people during this difficult time. At present we’re not able to confirm the key dates for this guidance topic
21 February 2020 Scope published
27 January 2020 Expected publication

For further information on how we develop guidance, please see our page about NICE medical technologies guidance